Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;82(3):683-95.
doi: 10.1111/bcp.13008. Epub 2016 Jun 30.

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity

Folefac Aminkeng  1   2 , Colin J D Ross  2   3 , Shahrad R Rassekh  2   4 , Soomi Hwang  5 , Michael J Rieder  6 , Amit P Bhavsar  2   3 , Anne Smith  2   7 , Shubhayan Sanatani  2 , Karen A Gelmon  8 , Daniel Bernstein  9 , Michael R Hayden  1   2   10 , Ursula Amstutz  2   3   11 , Bruce C Carleton  2   7 ; CPNDS Clinical Practice Recommendations Group
Affiliations
Review

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity

Folefac Aminkeng et al. Br J Clin Pharmacol. 2016 Sep.

Abstract

Aims: Anthracycline-induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence-based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk.

Methods: We followed a standard guideline development process, including a systematic literature search, evidence synthesis and critical appraisal, and the development of clinical practice recommendations with an international expert group.

Results: RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants currently have the strongest and the most consistent evidence for association with ACT. Genetic variants in ABCC1, ABCC2, ABCC5, ABCB1, ABCB4, CBR3, RAC2, NCF4, CYBA, GSTP1, CAT, SULT2B1, POR, HAS3, SLC22A7, SCL22A17, HFE and NOS3 have also been associated with ACT, but require additional validation. We recommend pharmacogenomic testing for the RARG rs2229774 (S427L), SLC28A3 rs7853758 (L461L) and UGT1A6*4 rs17863783 (V209V) variants in childhood cancer patients with an indication for doxorubicin or daunorubicin therapy (Level B - moderate). Based on an overall risk stratification, taking into account genetic and clinical risk factors, we recommend a number of management options including increased frequency of echocardiogram monitoring, follow-up, as well as therapeutic options within the current standard of clinical practice.

Conclusions: Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.

Keywords: anthracycline; cancer; cardiotoxicity; guidelines; heart-failure; pharmacogenomics.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Altekruse SF. Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al, eds. SEER Cancer Statistics Review 1975–2007. Bethesda: National Cancer Institute, 2010.
    1. Ellison LF, Pogany L, Mery LS. Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry. Eur J Cancer 2007; 43: 1967–75. - PubMed
    1. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long‐term survivors of childhood cancer. Cardiovasc Toxicol 2007; 7: 122–8. - PubMed
    1. Cancer Therapy Evaluation Program – Common Terminology Criteria for Adverse Events – Version 3, 2003.
    1. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819–29. - PubMed

MeSH terms

Substances

Grants and funding